Clinical trial Recruiting at 1 site Interventional Ages 14 to 19

Twice-daily rTMS for Depressed Youth in Hospital

Official title: Seamless Integration of Repetitive Transcranial Magnetic Stimulation (rTMS) for Youth Inpatients With Depression: A Feasibility Study

Run by Sunnybrook Health Sciences Centre · NCT07140575 · Data updated 2026-11-12

This project will test whether giving twice-daily repetitive transcranial magnetic stimulation (rTMS) to hospitalized adolescents with moderate-to-severe depression is feasible while they attend on-unit schooling and receive therapeutic support.

More Feasibility Studies trials

Quick facts

Study typeInterventional
Ages14 Years to 19 Years
SexAll
Enrollment30 (estimated)
SponsorSunnybrook Health Sciences Centre
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedAugust 2025
Main results expectedJuly 2027
Study endsDecember 2027
Registry record updatedAugust 24, 2025
Trial IDNCT07140575 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adolescents (about 14–19 years) hospitalized or eligible for elective admission with a primary major depressive episode (or bipolar depression without psychotic/mixed features), a current episode of at least 4 weeks, GRID-HAMD-17 ≥16, and prior nonresponse to at least one evidence-based psychotherapy or antidepressant.

Probably not a fit

Patients with a history of psychotic disorders, recent substance use disorder, active mania or psychosis, epilepsy or other seizure disorders, pregnancy or nursing, eating disorders as the primary diagnosis, or taking medications that lower the seizure threshold are unlikely to be eligible or benefit from this pathway.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center feasibility project offers an accelerated rTMS pathway for adolescents admitted with major depressive episodes, delivering rTMS twice daily while participants engage in inpatient schooling and therapeutic programming. Eligible participants are typically aged 14–19 with moderate-to-severe depression (GRID-HAMD-17 ≥16) who have not responded to at least one evidence-based psychotherapy or antidepressant. The study will monitor feasibility, tolerability, safety, and depressive symptom change using standard rating scales and clinical observation. The protocol is informed by prior rTMS work in youth and accelerated rTMS pilots in adults, but focuses specifically on the inpatient setting to address access and logistical barriers.

Why it matters

Potential benefit: If successful, this pathway could let hospitalized youth receive accelerated rTMS with fewer travel and schooling disruptions and faster access to neuromodulation for difficult-to-treat depression.

How similar studies have gone: rTMS has shown benefit in adolescents and young adults with treatment-resistant depression, and accelerated twice-daily protocols have been piloted in adults with encouraging safety and similar effectiveness, but data specifically for inpatient youth remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age 14-19 years
* primary diagnosis of major depressive disorder or of bipolar I or II disorder, current episode depressed with no psychotic or mixed features
* current episode of depression lasting at least 4 weeks
* failed ≥1 evidence-based psychotherapy or antidepressant
* have a GRID-HAMD-17 (17-item Hamilton Depression Rating Scale) score of ≥16 (moderate-severe range)
* currently an inpatient or suitable for an elective inpatient admission

Exclusion Criteria:

* lifetime diagnosis of a psychotic disorder, anorexia nervosa, bulimia nervosa diagnosis of a substance use disorder (except caffeine and tobacco) within the past year
* obsessive compulsive disorder or personality disorder that is the main source and driver of distress
* active psychosis and/or mania
* history of epilepsy or any other neurologic condition that includes a history of seizures
* use of medications that lower the seizure threshold
* pregnancy or nursing
* history of severe headaches within the previous year
* improvement in depressive symptom severity between screening and baseline by 25% or more
* inability to adhere to the protocol

Where it's running

  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.